BioCryst Pharmaceuticals
BCRX
#4539
Rank
S$3.22 B
Marketcap
S$12.71
Share price
1.97%
Change (1 day)
11.57%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : S$1.31 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are S$1.31 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31S$0.81 B-38.1%
2024-12-31S$1.31 B2.27%
2023-12-31S$1.28 B13.43%
2022-12-31S$1.13 B20.48%
2021-12-31S$0.93 B100.68%
2020-12-31S$0.46 B153.48%
2019-12-31S$0.18 B38.54%
2018-12-31S$0.13 B5.51%
2017-12-31S$0.12 B-1.07%
2016-12-31S$0.12 B21.01%
2015-12-31S$0.10 B30.47%
2014-12-31S$80.91 M27.75%
2013-12-31S$63.33 M-10.53%
2012-12-31S$70.79 M-18.89%
2011-12-31S$87.28 M54.21%
2010-12-31S$56.6 M-27.9%
2009-12-31S$78.51 M43.47%
2008-12-31S$54.72 M-51.13%
2007-12-31S$0.11 B54.28%
2006-12-31S$72.57 M6.82%
2005-12-31S$67.94 M1228.77%
2004-12-31S$5.11 M82.58%
2003-12-31S$2.8 M37.72%
2002-12-31S$2.03 M-51.87%
2001-12-31S$4.22 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Gilead Sciences
GILD
S$42.41 B 3,123.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$77.71 B 5,807.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
S$2.16 B 64.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$1.06 B-19.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
S$1.53 B 16.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
S$71.05 M-94.60%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
S$1.52 M-99.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
S$15.75 M-98.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
S$1.13 B-13.78%๐Ÿ‡บ๐Ÿ‡ธ USA